Virus Research Institute

Cambridge, MA 02138

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $0.0
First Award Date 09/30/93
Most Recent Award Date 09/30/97

Key Personnel

Last Name Name Awards Contact
Payne Lendon Payne 2
Lu Yichen Lu 4
Killeen Kevin Killeen 2
Lifter John Lifter 1
Ramstedt H Urban Ramstedt 1

10 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 03/30/98

DESCRIPTION: Virus Research Institute and Dana Farber Cancer Institute seeks support for pre-clinical gene transfer studies utilizing peripheral mononuclear cells, purified CD4+ T-cells from uninfected and HIV-1 infected individuals that will result in "Intracellular immunization" against HIV-1. The rese...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/97 - 09/29/98

The long term goal is the development of a practical, single-dose, oral, cholera vaccine for use in both industrialized and developing countries. The specific aims are to utilize the strain Peru 15, an attenuated El Tor, V. Cholerae 01, which has already proven to be safe, immunogenic and e...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/96 - 03/31/97

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/96 - 02/28/97
PI: Yichen Lu

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/95 - 07/31/95
PI: Yichen Lu

DESCRIPTION: (Adapted from the applicant's abstract) Vibrio cholera is a human pathogen that colonizes the gut and elicits both mucosal and systemic protective immune responses. Novel SIV prophylactics will be developed using a genetically attenuated strain of this organism to derive oral SIV vaccines. These new oral vaccines will be e...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/94 - 12/31/94
PI: Yichen Lu

Vibrio cholera and Typhi salmonella are human pathogens that colonize gut and elicit both mucosal and systemic protective immune responses. Novel HIV1 prophylactics will be developed using genetically attenuated strains of these organisms to derive single dose oral HIV1 vaccines. These new oral vaccines will be evaluated in the recently develo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/94 - 10/15/94

The majority of viral vaccines establish a state of systemic protective immunity by injection of live attenuated or inactivated virus preparations. The use of injectable vaccines has reduced the incidence of many viral diseases. Nevertheless, their usage is associated with some undesirable side effects. Live attenuated virus vaccines can cause...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/94 - 06/30/94

Modern molecular biology has provided us with a means of producing immunogens with unprecedented ease and precision but these new methodologies generate purified immunogens that do not generally induce a strong immune response in the absence of an effective adjuvant. The development of improved vaccine adjuvants for use in humans has therefore ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/93 - 03/29/94
PI: Yichen Lu

The problem with the current chimpanzee model for evaluating HIV prophylactics is both availability and cost of the animals. Similarly, the SIV model is limited since protection studies in primates illustrated that the immune protective epitopes of SIV envelope glycoprotein are structurally very different from its HIV counterpart. SHIV-LAI is ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/93 - 09/30/94

Vibrio cholerae vaccines which elicit antibodies against cholera toxin (CT) have been demonstrated to confer cross protection to human vaccinees against strains of heat-labile toxin (LT) producing enterotoxigenic E. coli (ETEC). Vaccinees were still vulnerable however to heat-stable toxin (ST) producing strains of ETEC. Virus Research Institut...

Load More